Filing Flows › Edwards Lifesciences (EW) › Transcatheter Aortic Valve Replacement revenue
Edwards Lifesciences (EW) Transcatheter Aortic Valve Replacement revenue by quarter
Edwards Lifesciences' Transcatheter Aortic Valve Replacement revenue was $1.2B in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 7 quarters it ranged from $1.0B (Q1 2025) to $1.3B (Q2 2026).
| Quarter | Transcatheter Aortic Valve Replacement revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.2B | -1% | +8% |
| Q2 2026 | $1.3B | +5% | +11% |
| Q1 2026 | $1.2B | +3% | +14% |
| Q4 2025 | $1.2B | +0.9% | — |
| Q3 2025 | $1.1B | +2% | — |
| Q2 2025 | $1.1B | +8% | — |
| Q1 2025 | $1.0B | — | — |
Q3 2026 at a glance
Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.
Questions
What is Edwards Lifesciences' Transcatheter Aortic Valve Replacement revenue?
Edwards Lifesciences' Transcatheter Aortic Valve Replacement revenue was $1.2B in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Edwards Lifesciences' Transcatheter Aortic Valve Replacement revenue changed?
Over the last 7 quarters it ranged from $1.0B (Q1 2025) to $1.3B (Q2 2026).